Sharescart Research Club logo

iSERA Lifesciences Overview

Covidh Technologies Ltd. is an Indian public limited company operating in the information technology (IT) and IT-enabled services (ITES) sector. It was incorporated in January 1993 in Hyderabad, Telangana, and has been active in the technology industry for over three decades. The company’s equity shares are listed on the Bombay Stock Exchange (BSE). Originally established under a different name, the company underwent several name changes before becoming Covidh Technologies Ltd. in 2014. Over its history, it has been involved in software deve...Read More

Want to Start Investing in Top Unlisted Stocks?

Our experts help you choose the right stocks based on performance, risk, and growth potential.

iSERA Lifesciences Key Financials

Market Cap ₹65 Cr.

Stock P/E 468.8

P/B 8.5

Current Price ₹77.5

Book Value ₹ 9.2

Face Value 10

52W High ₹77.5

Dividend Yield 0%

52W Low ₹ 0

iSERA Lifesciences Share Price

₹ | |

Volume
Price

iSERA Lifesciences Quarterly Price

Show Value Show %

iSERA Lifesciences Peer Comparison

iSERA Lifesciences Quarterly Results

#(Fig in Cr.) Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025
Net Sales 0 0 0 0 0 0 0 0 0 0
Other Income 0 0 0 0 0 0 0 0 0 0
Total Income 0 0 0 0 0 0 0 0 0 0
Total Expenditure 0 0 0 0 0 0 0 0 0 0
Operating Profit -0 -0 -0 -0 -0 -0 0 -0 0 -0
Interest 0 0 0 0 0 0 0 0 0 0
Depreciation 0 0 0 0 0 0 0 0 0 0
Exceptional Income / Expenses 0 0 0 0 0 0 0 0 0 0
Profit Before Tax -0 -0 -0 -0 -0 -0 0 -0 0 -0
Provision for Tax 0 0 0 0 0 0 0 0 0 0
Profit After Tax -0 -0 -0 -0 -0 -0 0 -0 0 -0
Adjustments 0 0 0 0 0 0 0 0 0 0
Profit After Adjustments -0 -0 -0 -0 -0 -0 0 -0 0 -0
Adjusted Earnings Per Share -0.7 -0.5 -2.7 -0.4 -0.5 -2.6 8.9 -0.6 0.3 -0.3

iSERA Lifesciences Profit & Loss

#(Fig in Cr.) Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 TTM
Net Sales 11 25 21 29 12 2 0 0 0 0 0 0
Other Income 0 0 0 0 0 0 0 0 0 0 0 0
Total Income 11 25 21 29 12 2 0 0 0 0 0 0
Total Expenditure 10 25 21 28 12 2 0 0 0 0 0 0
Operating Profit 1 0 0 0 0 -0 -0 -0 -0 -0 0 0
Interest 0 0 0 0 0 0 0 0 0 0 0 0
Depreciation 1 0 0 0 0 0 0 0 0 0 0 0
Exceptional Income / Expenses 0 -13 0 0 0 0 0 0 0 0 0 0
Profit Before Tax 0 -12 0 0 0 -0 -0 -0 -0 -0 0 0
Provision for Tax -0 0 0 0 0 0 0 0 0 0 0 0
Profit After Tax 0 -13 0 0 -0 -0 -0 -0 -0 -0 0 0
Adjustments 0 0 0 0 0 0 0 0 0 0 0 0
Profit After Adjustments 0 -13 0 0 -0 -0 -0 -0 -0 -0 0 0
Adjusted Earnings Per Share 0.1 -15 0 0 -0 -0.5 -0.3 0 -4.7 -3.9 5.4 8.3

Growth Rates

# 1 Year 3 Year 5 Year 10 Year
Sales CAGR 0% 0% -100% -100%
Operating Profit CAGR 0% 0% 0% -100%
PAT CAGR 0% 0% 0% 0%
# 1 Year 3 Year 5 Year 10 Year
Share Price CAGR 3717% 286% 158% 30%
ROE Average 0% 0% -1372% -652%
ROCE Average 19% -1710% -1029% -476%

iSERA Lifesciences Balance Sheet

#(Fig in Cr.) Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Shareholder's Funds 13 1 1 1 1 0 -0 -0 -0 -0 -0
Minority's Interest 0 0 0 0 0 0 0 0 0 0 0
Borrowings 5 5 5 6 6 7 2 0 0 0 2
Other Non-Current Liabilities 0 0 0 -0 0 0 0 0 0 0 0
Total Current Liabilities 2 6 7 10 6 4 3 0 0 0 0
Total Liabilities 21 11 13 16 12 10 4 0 0 0 2
Fixed Assets 7 0 0 0 1 1 0 0 0 0 0
Other Non-Current Assets 6 0 0 0 0 0 0 0 0 0 0
Total Current Assets 8 11 12 16 11 10 4 0 0 0 2
Total Assets 21 11 13 16 12 10 4 0 0 0 2

iSERA Lifesciences Cash Flow

#(Fig in Cr.) Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Opening Cash & Cash Equivalents 0 0 0 0 0 0 0 0 0 0 0
Cash Flow from Operating Activities 1 1 -1 -1 0 1 4 -0 -0 -0 -1
Cash Flow from Investing Activities -1 -0 -0 -0 -0 0 0 0 0 0 0
Cash Flow from Financing Activities 1 -0 1 1 0 -1 -5 0 0 0 1
Net Cash Inflow / Outflow 0 -0 -0 -0 0 0 -0 0 0 -0 0
Closing Cash & Cash Equivalent 0 0 0 0 0 0 0 0 0 0 0

iSERA Lifesciences Ratios

# Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Earnings Per Share (Rs) 0.14 -14.97 0.01 0.05 -0.02 -0.5 -0.26 0 -4.71 -3.87 5.44
CEPS(Rs) 0.74 -14.87 0.25 0.22 0.08 -0.35 -0.14 0 -4.71 -3.87 5.44
DPS(Rs) 0 0 0 0 0 0 0 0 0 0 0
Book NAV/Share(Rs) 15.57 0.6 0.61 0.65 0.63 0.13 -0.13 0 -4.94 -8.45 -3.83
Core EBITDA Margin(%) 5.72 1.42 2.09 1.59 2.61 -2.54 0 0 0 0 52.41
EBIT Margin(%) 1.1 -48.38 1.13 1.08 1.93 -8.3 0 0 0 0 52.41
Pre Tax Margin(%) 1.03 -48.98 0.17 0.15 0.07 -18.73 0 0 0 0 52.41
PAT Margin (%) 1.08 -49.19 0.02 0.13 -0.13 -19.57 0 0 0 0 52.41
Cash Profit Margin (%) 5.7 -48.87 0.98 0.64 0.55 -13.81 0 0 0 0 52.41
ROA(%) 0.57 -78.84 0.04 0.26 -0.11 -3.69 -2.92 -4.69 -433.51 -187.6 17.28
ROE(%) 0.91 -185.16 0.97 7.27 -2.91 -129.99 -6858.57 0 0 0 0
ROCE(%) 0.68 -99.98 3.45 4.07 2.94 -2.4 -4.64 -11.08 -5149.45 0 18.82
Receivable days 235.92 102.54 160.6 153.48 358 1591.36 0 0 0 0 430.65
Inventory Days 0 0 0 0 0 0 0 0 0 0 0
Payable days 0 0 0 0 0 0 0 0 0 0 0
PER(x) 74.49 0 467.47 0 0 0 0 0 0 0 0
Price/Book(x) 0.67 9.97 4.49 0 0.9 4.84 -5.14 0 -0.29 -0.24 0
Dividend Yield(%) 0 0 0 0 0 0 0 0 0 0 0
EV/Net Sales(x) 1.47 0.49 0.45 0.63 0.66 3.4 0 0 0 0 7.2
EV/Core EBITDA(x) 25.67 34.53 21.71 39.36 25.36 -133.82 -26.92 0.01 -1.48 -2.52 13.73
Net Sales Growth(%) -53.28 134.01 -16.23 35.4 -57.47 -82.66 -100 0 0 0 0
EBIT Growth(%) 46.15 0 101.96 29.62 -24.33 -174.78 -12.52 47.04 -5.94 11.55 240.61
PAT Growth(%) 188.55 0 100.04 679.45 -140.92 -2564.54 47.67 51.71 -5.93 11.55 240.61
EPS Growth(%) 188.58 0 100.04 684.78 -141 -2561.49 47.68 100 0 17.95 240.62
Debt/Equity(x) 0.38 12.24 13.46 13.74 14.22 58.37 -19 0 -1.07 -0.85 -16.38
Current Ratio(x) 3.1 1.74 1.76 1.59 2.01 2.62 1.6 0.18 1.21 0.64 33.7
Quick Ratio(x) 3.1 1.74 1.76 1.59 2.01 2.62 1.6 0.18 1.21 0.64 33.7
Interest Cover(x) 15.25 -79.43 1.18 1.16 1.04 -0.8 -11.21 -8940.68 0 0 0
Total Debt/Mcap(x) 0.45 0.97 2.37 0 12.47 9.53 2.93 0 2.94 3.03 0

iSERA Lifesciences Shareholding Pattern

# Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026
Promoter 26.35 26.35 26.35 26.35 26.35 92.76 92.76 92.76 3.57 58.63
FII 0 0 0 0 0 0 0 0 0 0
DII 0 0 0 0 0 0 0 0 0 0
Public 73.65 73.65 73.65 73.65 73.65 7.24 7.24 7.24 96.43 41.37
Others 0 0 0 0 0 0 0 0 0 0
Total 100 100 100 100 100 100 100 100 100 100

iSERA Lifesciences News

iSERA Lifesciences Pros & Cons

Pros

  • Company is almost debt free.

Cons

  • Company has a low return on equity of 0% over the last 3 years.
  • Stock is trading at 8.5 times its book value.
whatsapp